ERBB2 and gastroesophageal junction adenocarcinoma: Distamab vedotin has demonstrated safety and potent antitumor activity in a phase I trial in patients with advanced HER2-positive gastric cancer and has been approved in China as second-line treatment for patients with HER2-overexpressing advanced or metastatic gastric/gastroesophageal junction adenocarcinoma [42].